156100 — L&K Biomed Co Share Price
Last trade - 00:00- KR₩161bn
- KR₩161bn
- KR₩30bn
- 28
- 15
- 39
- 12
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 13.35 | ||
| PEG Ratio (f) | 0.59 | ||
| EPS Growth (f) | 29.09% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.57 | ||
| Price to Tang. Book | 4.67 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 5.4 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -31.7% | ||
| Return on Equity | -7.84% | ||
| Operating Margin | -42.4% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 26,575 | 19,356.05 | 15,372.57 | 19,767.46 | 29,904.81 | 61,200 | 94,500 | -0.92% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | -2.95 | +111.96 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
L&K BIOMED CO., LTD. is a Korea-based company mainly engaged in the research, development and manufacture of medical devices. The Company’s products consist of medical devices and medical equipment. Its medical devices include cervical spine products, such as cervical plate systems, cervical screw systems and cervical cage system, as well as thoracolumbar spine products and others. Its medical equipment includes three dimensional (3D) full-body scanners. It also engages in the bio-similar business, which develops cell engineering.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- December 22nd, 2008
- Public Since
- July 1st, 2013
- No. of Shareholders
- 16,954
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Korea Exchange - KOSDAQ
- Shares in Issue
- 19,936,733
- Address
- 301 475-42 Seogyo-dong, YONGIN, 17015
- Web
- http://www.lnkbiomed.com/
- Phone
- +82 267171911
- Auditors
- KPMG Samjong Accounting Corp
Upcoming Events for 156100
Similar to 156100
Access Bio
Korea Exchange - KOSDAQ
Aligned Genetics
Korea Exchange - KOSDAQ
Angel Robotics Co
Korea Exchange - KOSDAQ
Asta Co
Korea Exchange - KOSDAQ
Biodyne Co
Korea Exchange - KOSDAQ
FAQ
As of Today at 19:13 UTC, shares in L&K Biomed Co are trading at KR₩8,100. This share price information is delayed by 15 minutes.
Shares in L&K Biomed Co last closed at KR₩8,100 and the price had moved by +22.07% over the past 365 days. In terms of relative price strength the L&K Biomed Co share price has outperformed the FTSE Developed Asia Pacific Index by +22.91% over the past year.
There is no consensus recommendation for this security.
L&K Biomed Co does not currently pay a dividend.
L&K Biomed Co does not currently pay a dividend.
L&K Biomed Co does not currently pay a dividend.
To buy shares in L&K Biomed Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of KR₩8,100, shares in L&K Biomed Co had a market capitalisation of KR₩161bn.
Here are the trading details for L&K Biomed Co:
- Country of listing: Korea, Republic of
- Exchange: KOE
- Ticker Symbol: 156100
Based on an overall assessment of its quality, value and momentum L&K Biomed Co is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like L&K Biomed Co. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -12.87%.
As of the last closing price of KR₩8,100, shares in L&K Biomed Co were trading -1.81% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The L&K Biomed Co PE ratio based on its reported earnings over the past 12 months is 13.35. The shares last closed at KR₩8,100.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
L&K Biomed Co's management team is headed by:
- Guk Jin Kang - CEO
- Gyeong Jo Lee - OTH
- Jae Hyeon Ryu - NID
- Yeong Suk Son - NID